Joerger Andreas C, Stiewe Thorsten, Soussi Thierry
Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.
Structural Genomics Consortium (SGC), Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany.
Cell Death Differ. 2025 Feb;32(2):219-224. doi: 10.1038/s41418-024-01391-6. Epub 2024 Oct 23.
The transcription factor p53 plays a key role in the cellular defense against cancer development. It is inactivated in virtually every tumor, and in every second tumor this inactivation is due to a mutation in the TP53 gene. In this perspective, we show that this diverse mutational spectrum is unique among all other cancer-associated proteins and discuss what drives the selection of TP53 mutations in cancer. We highlight that several factors conspire to make the p53 protein particularly vulnerable to inactivation by the mutations that constantly plague our genome. It appears that the TP53 gene has emerged as a victim of its own evolutionary past that shaped its structure and function towards a pluripotent tumor suppressor, but came with an increased structural fragility of its DNA-binding domain. TP53 loss of function - with associated dominant-negative effects - is the main mechanism that will impair TP53 tumor suppressive function, regardless of whether a neomorphic phenotype is associated with some of these variants.
转录因子p53在细胞抵御癌症发展的过程中起着关键作用。实际上,在每一个肿瘤中它都是失活的,并且在每两个肿瘤中就有一个这种失活是由于TP53基因的突变所致。从这个角度来看,我们表明这种多样的突变谱在所有其他癌症相关蛋白中是独一无二的,并讨论了在癌症中驱动TP53突变选择的因素。我们强调,有几个因素共同作用,使得p53蛋白特别容易受到不断困扰我们基因组的突变的失活影响。似乎TP53基因已成为其自身进化史的受害者,其进化史将其结构和功能塑造为一种多能肿瘤抑制因子,但同时其DNA结合结构域的结构脆性增加。TP53功能丧失——伴有相关的显性负效应——是损害TP53肿瘤抑制功能的主要机制,无论这些变体中的一些是否与新形态表型相关。